BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36653885)

  • 1. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.
    Sheel A; Bae J; Asada A; Otterson GA; Baliga RR; Koenig KL
    Cardiooncology; 2023 Jan; 9(1):4. PubMed ID: 36653885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
    Patel AA; Cahill K; Saygin C; Odenike O
    Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
    Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
    Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
    Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
    Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine/Cedazuridine: First Approval.
    Dhillon S
    Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Thota S; Oganesian A; Azab M; Griffiths EA
    Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
    Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
    Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents for myelodysplastic syndromes.
    Xu K; Hansen E
    J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
    Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia.
    Briski R; Garcia-Manero G; Kantarjian H; Ravandi F
    Ther Adv Hematol; 2023; 14():20406207231205429. PubMed ID: 37854355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
    Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
    Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.
    Yun JP; Ding PQ; Dolley A; Cheung WY
    Curr Oncol; 2023 Aug; 30(9):8005-8018. PubMed ID: 37754496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
    Usuki K
    Rinsho Ketsueki; 2022; 63(9):1099-1106. PubMed ID: 36198535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
    Renneville A; Patnaik MM; Chan O; Padron E; Solary E
    Leukemia; 2021 Oct; 35(10):2739-2751. PubMed ID: 34175902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
    Kipp D; H Wei A
    Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
    Kim N; Norsworthy KJ; Subramaniam S; Chen H; Manning ML; Kitabi E; Earp J; Ehrlich LA; Okusanya OO; Vallejo J; Gehrke BJ; de Claro RA; Pazdur R
    Clin Cancer Res; 2022 Aug; 28(16):3411-3416. PubMed ID: 35435961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
    Schiffer M; Zhao J; Johnson A; Lee J; Bewersdorf JP; Zeidan AM
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):989-1002. PubMed ID: 33853476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
    Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
    Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
    Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
    Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.